Similar to Amplified in Osteosarcoma OS9；Protein OS-9 Precursor

Total Page：16

File Type：pdf, Size：1020Kb

Similar to Amplified in Osteosarcoma OS9；Protein OS-9 Precursor

ProteinTech Group, Inc 2201 W. Campbell Park Dr. Chicago, IL 60612 Toll Free: 1-888-4PTGLAB In Illinois: 1312-455-8498 FOR IN VITRO RESEARCH USE ONLY Fax: 1-312-455-8408 NOT FOR USE IN HUMANS OR ANIMALS Web: www.ptglab.com Similar to amplified in osteosarcoma OS9；Protein OS-9 precursor BC000532 About the antigen: The antibody is stored at 50% Glycerol in PBS o Three splice variants of OS-9 have been buffer containing 0.02% sodium azide at -20 C. identified, encoding 667, 617 and 597 amino The final concentration generally is 150 µg/ml for acid peptides for isoforms 1, 2 and 3, affinity purified antibody, 1 mg/ml for IgG fraction respectively. The expression of OS-9 is detected from protein A Sepharose. Glycerol was added in all 16 human tissues examined, suggesting to a final concentration of 50% to so that that OS-9 is ubiquitously expressed in human antibodies can be stored at -20 oC without going tissues. The OS-9 gene maps to a region (q13- through freeze-thaw cycles during shipping. 15) of chromosome 12 and is frequently co- amplified with CDK4 in human sarcomas. Northern blotting analyses reveal similar levels of expression of OS-9 gene in various tumor cell lines of sarcoma cells, carcinoma cells and Hela cell lysates were subjected 103 kd to 10% SDS PAGE followed by myeloid leukemia cells, but 3-4 times higher western blot with affinity purified expression in OsA-CL cells and Rh30 cells 70 kd containing a homogeneously staining region of Ab at dilution of 1:400 12q13-15. The function of mammalian OS-9 50 kd protein is not known. The Saccharomyces cerevisiae homolog protein, YOS9, is a membrane-associated glycoprotein that localizes to the endoplasmic reticulum (ER), and interacts genetically with genes involved in ER- Golgi transport. Yos9 plays a direct role in the transport of glycosylphosphatidylinositol (GPI)- anchored proteins to the Golgi apparatus. Yos9 binds directly to Gas1 and Mkc7 and accelerates Gas1 transport and processing in cells overexpressing YOS9. As Yos9 is not a component of the Emp24 complex, it may act as a novel escort factor for GPI-anchored proteins in ER-Golgi transport in yeast, and possibly in mammals. The antibody: Format 1: Affinity purified Catalog No. : 10061-1-AP Weight/Volume: 30 µg/150 µl Tested Applications: WB (1:400) IP: (5 µl/ml lysate) Immunogen: Hu, Partial. Tested Specificity: Mo, Hu, Rb, Rt. Host: Rb Antibody species: Polyclonal Storage Information: .

Copy Link

Recommended publications

Genome Sequence of the Progenitor of the Wheat D Genome Aegilops Tauschii Ming-Cheng Luo1*, Yong Q
OPEN LETTER doi:10.1038/nature24486 Genome sequence of the progenitor of the wheat D genome Aegilops tauschii Ming-Cheng Luo1*, Yong Q. Gu2*, Daniela Puiu3*, Hao Wang4,5,6*, Sven O. Twardziok7*, Karin R. Deal1, Naxin Huo1,2, Tingting Zhu1, Le Wang1, Yi Wang1,2, Patrick E. McGuire1, Shuyang Liu1, Hai Long1, Ramesh K. Ramasamy1, Juan C. Rodriguez1, Sonny L. Van1, Luxia Yuan1, Zhenzhong Wang1,8, Zhiqiang Xia1, Lichan Xiao1, Olin D. Anderson2, Shuhong Ouyang2,8, Yong Liang2,8, Aleksey V. Zimin3, Geo Pertea3, Peng Qi4,5, Jeffrey L. Bennetzen6, Xiongtao Dai9, Matthew W. Dawson9, Hans-Georg Müller9, Karl Kugler7, Lorena Rivarola-Duarte7, Manuel Spannagl7, Klaus F. X. Mayer7,10, Fu-Hao Lu11, Michael W. Bevan11, Philippe Leroy12, Pingchuan Li13, Frank M. You13, Qixin Sun8, Zhiyong Liu8, Eric Lyons14, Thomas Wicker15, Steven L. Salzberg3,16, Katrien M. Devos4,5 & Jan Dvořák1 Aegilops tauschii is the diploid progenitor of the D genome of We conclude therefore that the size of the Ae. tauschii genome is about hexaploid wheat1 (Triticum aestivum, genomes AABBDD) and 4.3 Gb. an important genetic resource for wheat2–4. The large size and To assess the accuracy of our assembly, sequences of 195 inde- highly repetitive nature of the Ae. tauschii genome has until now pendently sequenced and assembled AL8/78 BAC clones8, which precluded the development of a reference-quality genome sequence5. contained 25,540,177 bp in 2,405 unordered contigs, were aligned to Here we use an array of advanced technologies, including ordered- Aet v3.0. Five contigs failed to align and six extended partly into gaps, clone genome sequencing, whole-genome shotgun sequencing, accounting for 0.25% of the total length of the contigs.
[Show full text]
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Published OnlineFirst February 21, 2013; DOI: 10.1158/2159-8290.CD-12-0418 RESEARCH ARTICLE Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition Alexandre Puissant1,3, Stacey M. Frumm1,3, Gabriela Alexe1,3,5,6, Christopher F. Bassil1,3, Jun Qi2, Yvan H. Chanthery8, Erin A. Nekritz8, Rhamy Zeid2, William Clay Gustafson8, Patricia Greninger7, Matthew J. Garnett10, Ultan McDermott10, Cyril H. Benes7, Andrew L. Kung1,3, William A. Weiss8,9, James E. Bradner2,4, and Kimberly Stegmaier1,3,6 Downloaded from cancerdiscovery.aacrjournals.org on October 2, 2021. © 2013 American Association for Cancer Research. 15-CD-12-0418_p308-323.indd 1 22/02/13 12:15 AM Published OnlineFirst February 21, 2013; DOI: 10.1158/2159-8290.CD-12-0418 A BSTRACT Bromodomain inhibition comprises a promising therapeutic strategy in cancer, particularly for hematologic malignancies. To date, however, genomic biomarkers to direct clinical translation have been lacking. We conducted a cell-based screen of genetically defined cancer cell lines using a prototypical inhibitor of BET bromodomains. Integration of genetic features with chemosensitivity data revealed a robust correlation between MYCN amplification and sensitivity to bromodomain inhibition. We characterized the mechanistic and translational significance of this finding in neuroblastoma, a childhood cancer with frequent amplification of MYCN. Genome-wide expression analysis showed downregulation of the MYCN transcriptional program accompanied by suppression of MYCN transcription. Functionally, bromodomain-mediated inhibition of MYCN impaired growth and induced apoptosis in neuroblastoma. BRD4 knockdown phenocopied these effects, establishing BET bromodomains as transcriptional regulators of MYCN. BET inhibition conferred a significant survival advantage in 3 in vivo neuroblastoma models, providing a compelling rationale for developing BET bro- modomain inhibitors in patients with neuroblastoma.
[Show full text]
Bioinformatics Integrated Analysis to Investigate Candidate Biomarkers and Associated Metabolites in Osteosarcoma
Wang et al. Journal of Orthopaedic Surgery and Research (2021) 16:432 https://doi.org/10.1186/s13018-021-02578-0 RESEARCH ARTICLE Open Access Bioinformatics integrated analysis to investigate candidate biomarkers and associated metabolites in osteosarcoma Jun Wang, Mingzhi Gong, Zhenggang Xiong, Yangyang Zhao and Deguo Xing* Abstract Background: This study hoped to explore the potential biomarkers and associated metabolites during osteosarcoma (OS) progression based on bioinformatics integrated analysis. Methods: Gene expression profiles of GSE28424, including 19 human OS cell lines (OS group) and 4 human normal long bone tissue samples (control group), were downloaded. The differentially expressed genes (DEGs) in OS vs. control were investigated. The enrichment investigation was performed based on DEGs, followed by protein–protein interaction network analysis. Then, the feature genes associated with OS were explored, followed by survival analysis to reveal prognostic genes. The qRT-PCR assay was performed to test the expression of these genes. Finally, the OS- associated metabolites and disease-metabolic network were further investigated. Results: Totally, 357 DEGs were revealed between the OS vs. control groups. These DEGs, such as CXCL12, were mainly involved in functions like leukocyte migration. Then, totally, 38 feature genes were explored, of which 8 genes showed significant associations with the survival of patients. High expression of CXCL12, CEBPA, SPARCL1, CAT, TUBA1A, and ALDH1A1 was associated with longer survival time, while high expression of CFLAR and STC2 was associated with poor survival. Finally, a disease-metabolic network was constructed with 25 nodes including two disease-associated metabolites cyclophosphamide and bisphenol A (BPA). BPA showed interactions with multiple prognosis-related genes, such as CXCL12 and STC2.
[Show full text]
Os9) and the Hypoxia Response Gene, Hypoxia Inducible Factor 1 (Hif1) Alpha, in Kidney Tubular Cells
North Carolina Agricultural and Technical State University Aggie Digital Collections and Scholarship Theses Electronic Theses and Dissertations 2013 Meprin Interaction With Osteosarcoma 9 (Os9) And The Hypoxia Response Gene, Hypoxia Inducible Factor 1 (Hif1) Alpha, In Kidney Tubular Cells Barry L. Martin North Carolina Agricultural and Technical State University Follow this and additional works at: https://digital.library.ncat.edu/theses Recommended Citation Martin, Barry L., "Meprin Interaction With Osteosarcoma 9 (Os9) And The Hypoxia Response Gene, Hypoxia Inducible Factor 1 (Hif1) Alpha, In Kidney Tubular Cells" (2013). Theses. 287. https://digital.library.ncat.edu/theses/287 This Thesis is brought to you for free and open access by the Electronic Theses and Dissertations at Aggie Digital Collections and Scholarship. It has been accepted for inclusion in Theses by an authorized administrator of Aggie Digital Collections and Scholarship. For more information, please contact [email protected]. Meprin Interaction with Osteosarcoma 9 (OS9) and the Hypoxia Response Gene, Hypoxia- inducible Factor 1 (HIF1) Alpha, in Kidney Tubular Cells Barry L. Martin North Carolina A&T State University A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Department: Biology Major: Biology Major Professor: Dr. Elimelda Moige Ongeri Greensboro, North Carolina 2013 i School of Graduate Studies North Carolina Agricultural and Technical State University This is to certify that the Master’s Thesis of Barry L. Martin has met the thesis requirements of North Carolina Agricultural and Technical State University Greensboro, North Carolina 2013 Approved by: Elimelda Moige Ongeri, PhD Jian Han, PhD Major Professor Committee Member Catherine White, PhD Scott Harrison, PhD Committee Member Committee Member Mary Smith, PhD Sanjiv Sarin, PhD Department Chair Dean, The Graduate School ii © Copyright by Barry L.
[Show full text]
A Genome-Wide Association Study
ISSN (Online) 2287-3406 Journal of Life Science 2021 Vol. 31. No. 6. 568~573 DOI : https://doi.org/10.5352/JLS.2021.31.6.568 - Note - The Association of Long Noncoding RNA LOC105372577 with Endoplasmic Reticulum Protein 29 Expression: A Genome-wide Association Study Soyeon Lee1, Kiang Kwon2, Younghwa Ko3 and O-Yu Kwon3* 1School of Systems Biomedical Science, College of Natural Sciences, Soongsil University, Seoul 06978, Korea 2Department of Clinical Laboratory Science, Wonkwang Health Science University, Iksan 54538, Korea 3Department of Anatomy & Cell Biology, College of Medicine, Chungnam National University, Daejeon 35015, Korea Received April 27, 2021 /Revised April 29, 2021 /Accepted April 30, 2021 This study identified genomic factors associated with endoplasmic reticulum protein (ERp)29 gene ex- pression in a genome-wide association study (GWAS) of genetic variants, including single-nucleotide polymorphisms (SNPs). In total, 373 European genes from the 1000 Genomes Project were analyzed. SNPs with an allelic frequency of less than or more than 5% were removed, resulting in 5,913,563 SNPs including in the analysis. The following expression quantitative trait loci (eQTL) from the long noncoding RNA LOC105372577 were strongly associated with ERp29 expression: rs6138266 (p<4.172e10), rs62193420 (p<1.173e10), and rs6138267 (p<2.041e10). These were strongly expressed in the testis and in the brain. The three eQTL were identified through a transcriptome-wide association study (TWAS) and showed a significant association with ERp29 and osteosarcoma amplified 9 (OS9) expression. Upstream sequences of rs6138266 were recognized by ChIP-seq data, while HaploReg was used to demonstrate how its regulatory DNA binds upstream of transcription factor 1 (USF1).
[Show full text]
A SARS-Cov-2 Protein Interaction Map Reveals Targets for Drug Repurposing
Article A SARS-CoV-2 protein interaction map reveals targets for drug repurposing https://doi.org/10.1038/s41586-020-2286-9 A list of authors and affiliations appears at the end of the paper Received: 23 March 2020 Accepted: 22 April 2020 A newly described coronavirus named severe acute respiratory syndrome Published online: 30 April 2020 coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than Check for updates 160,000 individuals and caused worldwide social and economic disruption1,2. There are no antiviral drugs with proven clinical efcacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and eforts to develop drugs and vaccines are hampered by the limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identifed the human proteins that physically associated with each of the SARS-CoV-2 proteins using afnity-purifcation mass spectrometry, identifying 332 high-confdence protein–protein interactions between SARS-CoV-2 and human proteins. Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clinical trials and 28 are preclinical compounds). We screened a subset of these in multiple viral assays and found two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.
[Show full text]
Quantitative Trait Loci Mapping of Macrophage Atherogenic Phenotypes
QUANTITATIVE TRAIT LOCI MAPPING OF MACROPHAGE ATHEROGENIC PHENOTYPES BRIAN RITCHEY Bachelor of Science Biochemistry John Carroll University May 2009 submitted in partial fulfillment of requirements for the degree DOCTOR OF PHILOSOPHY IN CLINICAL AND BIOANALYTICAL CHEMISTRY at the CLEVELAND STATE UNIVERSITY December 2017 We hereby approve this thesis/dissertation for Brian Ritchey Candidate for the Doctor of Philosophy in Clinical-Bioanalytical Chemistry degree for the Department of Chemistry and the CLEVELAND STATE UNIVERSITY College of Graduate Studies by ______________________________ Date: _________ Dissertation Chairperson, Johnathan D. Smith, PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, David J. Anderson, PhD Department of Chemistry, Cleveland State University ______________________________ Date: _________ Dissertation Committee member, Baochuan Guo, PhD Department of Chemistry, Cleveland State University ______________________________ Date: _________ Dissertation Committee member, Stanley L. Hazen, MD PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, Renliang Zhang, MD PhD Department of Cellular and Molecular Medicine, Cleveland Clinic ______________________________ Date: _________ Dissertation Committee member, Aimin Zhou, PhD Department of Chemistry, Cleveland State University Date of Defense: October 23, 2017 DEDICATION I dedicate this work to my entire family. In particular, my brother Greg Ritchey, and most especially my father Dr. Michael Ritchey, without whose support none of this work would be possible. I am forever grateful to you for your devotion to me and our family. You are an eternal inspiration that will fuel me for the remainder of my life. I am extraordinarily lucky to have grown up in the family I did, which I will never forget.
[Show full text]
Supplementary Table 1. Hypermethylated Loci in Estrogen-Pre-Exposed Stem/Progenitor-Derived Epithelial Cells
Supplementary Table 1. Hypermethylated loci in estrogen-pre-exposed stem/progenitor-derived epithelial cells. Entrez Gene Probe genomic location* Control# Pre-exposed# Description Gene ID name chr5:134392762-134392807 5307 PITX1 -0.112183718 6.077605311 paired-like homeodomain transcription factor 1 chr12:006600331-006600378 171017 ZNF384 -0.450661784 6.034362758 zinc finger protein 384 57121 GPR92 G protein-coupled receptor 92 chr3:015115848-015115900 64145 ZFYVE20 -1.38491748 5.544950925 zinc finger, FYVE domain containing 20 chr7:156312210-156312270 -2.026450994 5.430611412 chr4:009794114-009794159 9948 WDR1 0.335617144 5.352264173 WD repeat domain 1 chr17:007280631-007280676 284114 TMEM102 -2.427266294 5.060047786 transmembrane protein 102 chr20:055274561-055274606 655 BMP7 0.764898513 5.023260524 bone morphogenetic protein 7 chr10:088461669-088461729 11155 LDB3 0 4.817869864 LIM domain binding 3 chr7:005314259-005314304 80028 FBXL18 0.921361233 4.779265347 F-box and leucine-rich repeat protein 18 chr9:130571259-130571313 59335 PRDM12 1.123111331 4.740306098 PR domain containing 12 chr2:054768043-054768088 6711 SPTBN1 -0.089623066 4.691756995 spectrin, beta, non-erythrocytic 1 chr10:070330822-070330882 79009 DDX50 -2.848748309 4.691491169 DEAD (Asp-Glu-Ala-Asp) box polypeptide 50 chr1:162469807-162469854 54499 TMCO1 1.495802762 4.655023656 transmembrane and coiled-coil domains 1 chr2:080442234-080442279 1496 CTNNA2 1.296310425 4.507269831 catenin (cadherin-associated protein), alpha 2 347730 LRRTM1 leucine rich repeat transmembrane
[Show full text]
Genome Sequence of the Progenitor of the Wheat D Genome Aegilops Tauschii Ming-Cheng Luo1*, Yong Q
OPEN LETTER doi:10.1038/nature24486 Genome sequence of the progenitor of the wheat D genome Aegilops tauschii Ming-Cheng Luo1*, Yong Q. Gu2*, Daniela Puiu3*, Hao Wang4,5,6*, Sven O. Twardziok7*, Karin R. Deal1, Naxin Huo1,2, Tingting Zhu1, Le Wang1, Yi Wang1,2, Patrick E. McGuire1, Shuyang Liu1, Hai Long1, Ramesh K. Ramasamy1, Juan C. Rodriguez1, Sonny L. Van1, Luxia Yuan1, Zhenzhong Wang1,8, Zhiqiang Xia1, Lichan Xiao1, Olin D. Anderson2, Shuhong Ouyang2,8, Yong Liang2,8, Aleksey V. Zimin3, Geo Pertea3, Peng Qi4,5, Jeffrey L. Bennetzen6, Xiongtao Dai9, Matthew W. Dawson9, Hans-Georg Müller9, Karl Kugler7, Lorena Rivarola-Duarte7, Manuel Spannagl7, Klaus F. X. Mayer7,10, Fu-Hao Lu11, Michael W. Bevan11, Philippe Leroy12, Pingchuan Li13, Frank M. You13, Qixin Sun8, Zhiyong Liu8, Eric Lyons14, Thomas Wicker15, Steven L. Salzberg3,16, Katrien M. Devos4,5 & Jan Dvořák1 Aegilops tauschii is the diploid progenitor of the D genome of We conclude therefore that the size of the Ae. tauschii genome is about hexaploid wheat1 (Triticum aestivum, genomes AABBDD) and 4.3 Gb. an important genetic resource for wheat2–4. The large size and To assess the accuracy of our assembly, sequences of 195 inde- highly repetitive nature of the Ae. tauschii genome has until now pendently sequenced and assembled AL8/78 BAC clones8, which precluded the development of a reference-quality genome sequence5. contained 25,540,177 bp in 2,405 unordered contigs, were aligned to Here we use an array of advanced technologies, including ordered- Aet v3.0. Five contigs failed to align and six extended partly into gaps, clone genome sequencing, whole-genome shotgun sequencing, accounting for 0.25% of the total length of the contigs.
[Show full text]
Mouse Os9 Knockout Project (CRISPR/Cas9)
https://www.alphaknockout.com Mouse Os9 Knockout Project (CRISPR/Cas9) Objective: To create a Os9 knockout Mouse model (C57BL/6J) by CRISPR/Cas-mediated genome engineering. Strategy summary: The Os9 gene (NCBI Reference Sequence: NM_001171026 ; Ensembl: ENSMUSG00000040462 ) is located on Mouse chromosome 10. 15 exons are identified, with the ATG start codon in exon 1 and the TGA stop codon in exon 15 (Transcript: ENSMUST00000164259). Exon 6~12 will be selected as target site. Cas9 and gRNA will be co-injected into fertilized eggs for KO Mouse production. The pups will be genotyped by PCR followed by sequencing analysis. Note: Exon 6 starts from about 28.77% of the coding region. Exon 6~12 covers 51.39% of the coding region. The size of effective KO region: ~2364 bp. The KO region does not have any other known gene. Page 1 of 8 https://www.alphaknockout.com Overview of the Targeting Strategy Wildtype allele 5' gRNA region gRNA region 3' 1 6 7 8 9 10 11 12 15 Legends Exon of mouse Os9 Knockout region Page 2 of 8 https://www.alphaknockout.com Overview of the Dot Plot (up) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 2000 bp section upstream of Exon 6 is aligned with itself to determine if there are tandem repeats. No significant tandem repeat is found in the dot plot matrix. So this region is suitable for PCR screening or sequencing analysis. Overview of the Dot Plot (down) Window size: 15 bp Forward Reverse Complement Sequence 12 Note: The 852 bp section downstream of Exon 12 is aligned with itself to determine if there are tandem repeats.
[Show full text]
The Architecture and Evolution of Cancer Neochromosomes
Cancer Cell Article The Architecture and Evolution of Cancer Neochromosomes Dale W. Garsed,1,8,9,15 Owen J. Marshall,5,15,17 Vincent D.A. Corbin,2,3,13,15 Arthur Hsu,2,15 Leon Di Stefano,2 Jan Schro¨ der,2,3 Jason Li,1 Zhi-Ping Feng,2,3 Bo W. Kim,5 Mark Kowarsky,2 Ben Lansdell,2 Ross Brookwell,6 Ola Myklebost,10 Leonardo Meza-Zepeda,10 Andrew J. Holloway,1 Florence Pedeutour,7 K.H. Andy Choo,5 Michael A. Damore,11 Andrew J. Deans,12 Anthony T. Papenfuss,2,3,4,8,13,16,* and David M. Thomas1,8,14,16,* 1Cancer Genomics, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia 2Bioinformatics Division, The Walter & Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia 3Department of Medical Biology, University of Melbourne, VIC 3010, Australia 4Department of Mathematics and Statistics, University of Melbourne, VIC, 3010, Australia 5Chromosome Research, Murdoch Childrens Research Institute, and Department of Paediatrics, Royal Children’s Hospital, University of Melbourne, Parkville, VIC 3052, Australia 6Sullivan Nicolaides Pathology, Indooroopilly, QLD 4068, Australia 7Laboratory of Solid Tumors Genetics, Nice University Hospital, Nice 06107, France 8Sir Peter MacCallum Department of Oncology, University of Melbourne, VIC 3010, Australia 9Department of Pathology, University of Melbourne, VIC 3010, Australia 10Department of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo 0424, Norway 11Amgen, Thousand Oaks, CA 91320, USA 12St Vincent’s Institute, Fitzroy, VIC 3065, Australia 13Bioinformatics
[Show full text]
Use of Chronic Lymphocytic Leukemia Research
USE OF CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM DATA REPOSITORY AND GENE EXPRESSION OMNIBUS TO GENERATE AND TEST HYPOTHESES FOR BIOMARKER IDENTIFICATION AND DEVELOPMENT THESIS Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Kristin Chelsea Keen, B.A. ***** The Ohio State University 2009 Thesis Committee: Approved by Professor Kun Huang, adviser Professor Philip Payne ______________________________ Adviser Pathology Graduate Program ABSTRACT Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United States. There is no known cure for CLL. While biomarkers have been found to correlate with disease progression, such as CD38, IGHV, and ZAP-70, there is a need for further validation of these biomarkers as well as new biomarker discovery. In this study, publicly available gene expression data from NCBI’s Gene Expression Omnibus was used to identify genes with expression correlated to ZAP-70 and CD38 mRNA expression patterns. Also utilized were vast amounts of data from the Chronic Lymphocytic Leukemia Research Consortium (CRC) to search for novel correlations between clinical markers and disease progression and treatment outcome. We found several hundred genes with expression patterns correlated to ZAP-70. We also found several clinical, genetic, biologic, and immunologic CRC data fields which were correlated significantly and at weakly to strongly associated. ii Dedicated to my family iii ACKNOWLEDGEMENTS I thank my adviser, Kun Huang, for his positive support and trust in me as a student and a researcher. I thank my committee member, Philip Payne, for his tangible enthusiasm and thoughtful advice.
[Show full text]